6 pharma and biotech companies with strong momentum

1. OneView Healthcare PLC (ASX: ONE) 

OneView’s share price surged over 100% in May, as the Company’s latest results came in better than expected. Receipts during 1Q’CY23 came in 34% higher than the pcp and the Company’s operating cash outflow improved substantially on the pcp, albeit still an outflow. 

During the quarter, OneView added 3,000 new beds, and major healthcare providers such as NYU’s Langone hospital, and also saw contract flow from a number of European healthcare centres where it received preferred tenders. In addition, there were also contracts from Thailand, where Bumrungrad Hospital will receive 600 beds for Gen 3. The Company added A$ 9.3 million in TCV sales in 1Q’CY23, with an annualised recurring revenue of A$1.8 million.

Healthcare administrative costs have risen significantly over the years, resulting in an increased need for solutions that address the need to reduce these costs. OneView is one such company addressing the needs of healthcare networks to help reduce their ancillary costs.

The global healthcare cloud computing market, including patient records, is expected to reach $90-$95 billion by 2027 growing at 20% a year, which provides a significant opportunity for OneView. The US on average spends around USD$2,500 per patient on healthcare administration; meanwhile, Canada spends around USD$550. Differences in the costs are significant despite similar levels of productivity and healthcare providers will be looking to bring those costs down however they can.

2. Neuroscientific Biopharmaceuticals Ltd (ASX: NSB) 

Neuroscientific’s share price increased 30% in May, driven by the Company’s lead peptide, EmtinB, which showed significant treatment effect “in a Gold Standard MOG-EAE induced model of Multiple Sclerosis” (MS). The treatment showed initial delay in progression of EAE clinical symptoms, displaying neuro-protective effects. The preclinical data will be used to complete the efficacy section for Neuroscientific’s planned submission for its Phase 1 human trials. 

Nueroscientific has developed multiple uses for its drug, EmbtinB, including BACE inhibitor drugs for Alzheimer's, drugs that seek to block BACE enzymes involved in the production of forming amyloid plaque. The Company derives its competitive advantage from treatment of pathways for Alzheimer's. Currently, most treatment protocols look to target the removal of amyloid plaque primarily from the brain. Such treatments have shown some success in delaying the onset of Alzheimer’s. Neuroscientific’s treatment is different as it looks to block the enzyme associated with amyloid plaque at the source, which could provide the next big breakthrough in the treatment of the disease. Neuroscientific believes EmbtinB can modulate microglia induced euroinflammation in Alzheimer's Disease, and “to activate neuronal pro-survival pathways leading to axonal regeneration is a game changing approach towards Alzheimer’s Disease”. 

Both diseases, but especially Alzheimer’s, is becoming a significant issue, with an aging global population and increasing incidences of the disease due to a varied number of reasons, which means the market for treatment will continue to grow at for the foreseeable future. There are currently no treatments that cure Alzheimer’s. Several novel treatments have achieved onset delay, but a permanent solution remains distant.

3. Telix Pharmaceuticals Limited (ASX: TLX) 

Telix Pharmaceuticals shares have continued to rally with the share price rising 16% in May. The share price up 151% over the 12-months to May-end. The share price is being driven by growth in the Company’s Illucix product, with the Company reporting total revenue of $100.1 million in 1Q’CY23. Sales of Illucix was up 27% on the pcp. During the first quarter, customer receipts increased by 15%, quarter-on-quarter, and net operating cash flow came in at $2.4 million. Meanwhile, gross margins came in at 63% 

Illucix, the sales of which hit a total of $97.5 million in 1Q'CY23, is expected to be rolled out globally, with commercial availability across Canada, Europe, Latin America, and China, which could significantly boost revenue moving forward. The global rollout should add significantly to the topline and could send the stock up further, as results continue to come in.

4. Immutep Limited (ASX: IMM) 

Immutep’s shares surged (but have since retreated) as results came in regarding its Efti Combination treatment with Pembrolizumab, an anti-PD-1 immunotherapy drug for non-small cell lung cancer. KEYTRUDA is currently one of the foremost immunotherapy drugs on the market. And, any combination treatment provides a significant market opportunity for the ancillary drug. 

Results were positive and showed that the combination achieved robust initial Overall Survival (OS) in 1st line non-small cell lung cancer (1L NSCLC) patients in the Phase II TACTI-002 trial.

The Company raised a total of $67.9 million at a price of $0.26 per share consisting of $50 million under a Placement and $17.9 million under an Institutional Entitlement Offer. The capital raised takes the cash balance to $135.2 million, which should see it through the current and expanded clinical program.

5. Mesoblast Limited (ASX: MSB) 

Mesoblasts’s shares increased 18% in May to be trading at $1.015 per share at May-end. This remains substantially below the highs of $5.70 in 2020. 

The Company replenished it’s balance sheet in late April raising US$40 million in a private placement to existing shareholders. 

Mesoblast is primarily involved in developing and marketing proprietary mesenchymal lineage cell technology platforms to develop and commercialize innovative allogeneic cellular medicines to treat complex inflammatory diseases resistant to conventional standards of care. Mesoblast currently has many Phase-3 treatments, including, Remestemcel-L steroid-refractory acute graft versus host disease.

6. Island Pharmaceuticals Limited (ASX: ILA) 

Island Pharmaceuticals shares surged 51%, as the Company received the go-ahead from the FDA for its ISLA-101 program. The mid-clinical stage company’s ISLA-101 drug is primarily used for the treatment of dengue fever and other mosquito-borne (or vector) diseases.

The study aims to ensure that administered doses could safely achieve blood concentrations of ISLA-101 that are predicated to be effective against the dengue virus. Dengue treatment is expected to grow at a rate of 20% CAGR over the next ten years and will reach a total of $5 billion by 2033. Developing countries represent the vast majority of Dengue cases, with Brazil, and Indonesia being the largest sources. 

There are currently 20+ companies working on dengue drug discovery each at different stages of the clinical process, including Abivax, Takeda, Merck, Immunoforge, and Glaxokline Smith. Essential pipeline drugs include anti-RNA inhibitor therapy (ABX220), and TAK-003, which demonstrated continued protection against dengue post hospitalisation.

This article was written by Parth Pala.